Online tool allows researchers to track genetic structure of SARS-CoV-2
An artificial intelligence platform available online has been designed to help researchers track the genetics of SARS-CoV-2 as it moves from person to person.
List view / Grid view
An artificial intelligence platform available online has been designed to help researchers track the genetics of SARS-CoV-2 as it moves from person to person.
Researchers recently conducted a genome-wide association study (GWAS) to identify factors that increase susceptibility to the incurable lung condition idiopathic pulmonary fibrosis (IPF). Here, Dr Richard Allen shares some of the study’s key findings.
After analysing the genomic diversity in SARS-CoV-2 by screening over 7,500 viruses from infected patients, researchers have offered clues for COVID-19 drug development.
Next-generation sequencing has revealed an 81-base pair mutation of the SARS-CoV-2 virus, which could be used to develop new antivirals or vaccines.
Researchers have unravelled the viral transcriptome and translatome of the herpes simplex virus (HSV-1) to aid disease research and immunotherapy.
The visualisation platform is being used to analyse how the SARS-CoV-2 virus causing COVID-19 is evolving and could be used to inform drug design.
Austrian researchers reveal the first 21 SARS-CoV-2 viral genomes as part of their project to aid in international understanding of how the virus causing COVID-19 mutates.
Dr Kutschera discusses the differences between males and females in relation to infection from the COVID-19 coronavirus.
Researchers have used the genome of Erysimum cheiranthoides (wormseed wallflower) to understand how plants biosynthesise cardenolides.
Researchers have used CRISPR-Cas9 to screen the genome for possible targets that could be used in potential treatments for muscular dystrophy.
Detailed knowledge of the human genome can provide us with extensive information about the causes of disease and how patients will respond to treatments. In this article, Pushpanathan Muthuirulan explores the concept of genetic testing and the potential for pharmacogenomic testing to transform healthcare.
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
A novel therapy, tested ex vivo, has been successful at correcting the dysfunctional body mechanism in Postural Orthostatic Tachycardia Syndrome (POTS).
A new study has created an atlas of human thymus development, to reveal which genes are needed for the production of specific T cells.
Results of an international collaboration show promise for the future of motor neurone disease treatment efforts, as protective gene is identified.